-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $8

Benzinga·07/08/2026 09:08:03
Listen to the news
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Annovis Bio (NYSE:ANVS) with a Buy rating and announces Price Target of $8.